Olrich sold 3,948 shares of DocuSign stock in a transaction dated Tuesday, April 5th. As a group, analysts anticipate that DocuSign will post -0.22 earnings per share for the current fiscal year.
DocuSign’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) EPS. The business had revenue of $588.69 million for the quarter, compared to analyst estimates of $581.85 million. DocuSign had a negative return on equity of 19.06% and a negative net margin of 4.00%. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.08). Get DocuSign alerts:ĭocuSign ( NASDAQ:DOCU – Get Rating) last posted its quarterly earnings data on Thursday, June 9th. Based on data from, DocuSign has an average rating of “Hold” and a consensus target price of $134.27. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company. Finally, William Blair lowered shares of DocuSign from an “outperform” rating to a “market perform” rating in a report on Friday. Bank of America lowered DocuSign from a “buy” rating to a “neutral” rating and lowered their target price for the company from $120.00 to $72.00 in a research note on Friday. Citigroup reduced their target price on shares of DocuSign from $137.00 to $114.00 and set a “buy” rating on the stock in a report on Friday, March 11th. UBS Group cut their target price on shares of DocuSign from $170.00 to $110.00 and set a “neutral” rating on the stock in a research note on Monday, March 7th. Oppenheimer cut DocuSign from an “outperform” rating to a “market perform” rating in a report on Friday, March 11th. JMP Securities’ target price points to a potential upside of 129.03% from the company’s current price.Ī number of other brokerages have also recently issued reports on DOCU.
The brokerage presently has a “market outperform” rating on the stock. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.DocuSign ( NASDAQ:DOCU – Get Rating) had its price objective cut by stock analysts at JMP Securities from $180.00 to $151.00 in a research report issued on Friday, The Fly reports. For additional Company information, please visit and follow us on Twitter and LinkedIn. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. PolyPid’s lead product candidate D-PLEX 100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections.
Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Investors interested in meeting with PolyPid during the conference should contact their JMP representative. JMP Securities 2022 Life Sciences Conference: PETACH TIKVA, Israel, J(GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.
0 kommentar(er)
